| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/02/2005 | WO2005049068A1 Use of interferon tau for the treatment of obesity and for promotion of weight loss |
| 06/02/2005 | WO2005049048A1 Fiber rich fraction of trigonella foenum-graecum and its use as a pharmaceutcal excipient |
| 06/02/2005 | WO2005049025A1 Method and composition for treatment of cutaneous lesions |
| 06/02/2005 | WO2005049024A2 Solid pharmaceutical preparation form |
| 06/02/2005 | WO2005049017A1 Anti-inflammatory, regenerating and antimicrobial composition |
| 06/02/2005 | WO2005049007A1 Prevention and measures for viral infection |
| 06/02/2005 | WO2005049004A1 Plaster |
| 06/02/2005 | WO2005049003A1 Extended release dosage forms of bupropion hydrochloride |
| 06/02/2005 | WO2005048997A1 Nanoparticles for delivery of a pharmacologically active agent |
| 06/02/2005 | WO2005048996A2 Modified release dosage forms of skeletal muscle relaxants |
| 06/02/2005 | WO2005048995A1 Iron salt coated with alginate and method for the preparation thereof |
| 06/02/2005 | WO2005048994A1 New formulation for retinoid-containing soft gelatin capsules |
| 06/02/2005 | WO2005048993A2 Minimization of drug oxidation in drug irradiated excipients formulations |
| 06/02/2005 | WO2005048992A1 Process for preparing clopidogrel compositions |
| 06/02/2005 | WO2005048991A1 Fosinopril composition |
| 06/02/2005 | WO2005048990A2 Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer |
| 06/02/2005 | WO2005048989A1 Excipients in drug delivery vehicles |
| 06/02/2005 | WO2005048988A1 Charged liposomes/micelles with encapsulated medical compounds |
| 06/02/2005 | WO2005048986A1 Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents |
| 06/02/2005 | WO2005048985A2 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 06/02/2005 | WO2005048984A1 Methods of preparing a foam comprising a sclerosing agent |
| 06/02/2005 | WO2005048983A1 Methods of preparing a foam comprising a sclerosing agent |
| 06/02/2005 | WO2005048982A2 Efficient introduction of an aerosol into a ventilator circuit |
| 06/02/2005 | WO2005048981A1 Controlled release of topirimate in liquid dosage forms |
| 06/02/2005 | WO2005048980A1 Composition for oral consumable film |
| 06/02/2005 | WO2005048979A2 Pharmaceutical composition having casing with multiple micro tablets |
| 06/02/2005 | WO2005048978A2 A controlled release pharmaceutical composition and a process for preparing the same |
| 06/02/2005 | WO2005048977A2 Therapeutic foam comprising a sclerosing solution |
| 06/02/2005 | WO2005048976A2 Foams comprising a sclerosing and a viscosity enhancing agent, methods for production thereof |
| 06/02/2005 | WO2005048975A1 Non-tabletted, chewable, individually dosed administration forms |
| 06/02/2005 | WO2005048974A2 Non-tabletted, chewable, individually dosed administration forms |
| 06/02/2005 | WO2005048965A2 Method and composition for breath freshening |
| 06/02/2005 | WO2005048947A2 Oral delivery system and method for making same |
| 06/02/2005 | WO2005048931A2 Dissolving thin film xanthone supplement |
| 06/02/2005 | WO2005048930A2 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 06/02/2005 | WO2005048927A2 Methods and reagents for the treatment of inflammatory disorders |
| 06/02/2005 | WO2005048923A2 Extended release venlafaxine formulation |
| 06/02/2005 | WO2005048911A2 Silicone products and methods for making silicone products |
| 06/02/2005 | WO2005048731A2 Lecithin-containing granular compositions and methods of their preparation |
| 06/02/2005 | WO2005048709A1 Use of panthenol in teat dip/spray preparations |
| 06/02/2005 | WO2005041932A3 Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same |
| 06/02/2005 | WO2005041889A3 Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants |
| 06/02/2005 | WO2005034979A3 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 06/02/2005 | WO2005034954A3 Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation |
| 06/02/2005 | WO2005034927A3 Aerosol formulation comprising formoterol in suspension |
| 06/02/2005 | WO2005027875B1 Particles |
| 06/02/2005 | WO2005018565A3 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof |
| 06/02/2005 | WO2005016225A3 Stable pharmaceutical composition of rabeprazole |
| 06/02/2005 | WO2005009380A3 Pharmaceutical formulations |
| 06/02/2005 | WO2004112762A3 Pharmaceutical formulations of amyloid inhibiting compounds |
| 06/02/2005 | WO2004100925A3 Dissolvable backing layer for use with a transmucosal delivery device |
| 06/02/2005 | WO2004087098A3 Preserved ophthalmic compositions |
| 06/02/2005 | WO2004034975A3 Sustained release profile modification |
| 06/02/2005 | US20050119629 Device and method for exothermic treatment of eyelid diseases |
| 06/02/2005 | US20050119502 (Dialkylamino, morpholino, or imidazolyl)-alkoxyphenolic derivatives as drug delivery agents; improved bioavailability for oral administration |
| 06/02/2005 | US20050119385 Process for production of pressure-sensitive adhesive moldings comprising crosslinked polymers as the main component |
| 06/02/2005 | US20050119343 Crystalline form; inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase; for oral administration |
| 06/02/2005 | US20050119340 Reversed cubic phase or reversed hexagonal phase liquid crystal; provide sustained action and/or reduced dosage requirements; bupivacaine |
| 06/02/2005 | US20050119331 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| 06/02/2005 | US20050119313 Aqueous antiseptic based on bispyridiniumalkanes |
| 06/02/2005 | US20050119307 Method of treating attention deficit disorders with D-threo methylphenidate |
| 06/02/2005 | US20050119299 Ophthalmic solutions containing tetrazole derivatives |
| 06/02/2005 | US20050119281 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom |
| 06/02/2005 | US20050119254 Antitumor agents; using taurolidine; administering into lungs |
| 06/02/2005 | US20050119219 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
| 06/02/2005 | US20050119216 Pharmaceutical compositions and methods relating to fucans |
| 06/02/2005 | US20050119202 Medicament to treat a fibrotic disease |
| 06/02/2005 | US20050119193 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same |
| 06/02/2005 | US20050119172 Purity, genetic engineered human serum albumin for Factor viii |
| 06/02/2005 | US20050119162 Anxiolytic agents; using transferrins; quality of life for cancer patients; antiarthritic agents; antiinflammatory agents; compaction; uniform particle size |
| 06/02/2005 | US20050119160 Administering pyrimidopyrimidine compound such as dipyridamole with methotrexate or aspirin |
| 06/02/2005 | US20050118425 Microcapsules containing biomedical materials |
| 06/02/2005 | US20050118288 Method for producing high-quality hydropbic licorice extract |
| 06/02/2005 | US20050118281 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent. |
| 06/02/2005 | US20050118276 Coated metal pyrithione particles for treatment of microorganisms |
| 06/02/2005 | US20050118275 vaccines; forming a water-in-oil-in-water emulsion that contains water, organic solvent and biodegradable polymer, followed by removal of the organic solvent from the emulsion to form microparticles, after which toxoid and/or polysaccharide containing antigens are adsorbed on the microparticles |
| 06/02/2005 | US20050118273 Microcapsules and oral composition containing the same |
| 06/02/2005 | US20050118272 Micronized pharmaceutical or nutraceutical powder with immediate release |
| 06/02/2005 | US20050118271 Polytartrate composition |
| 06/02/2005 | US20050118270 Method of formation of shape-retentive aggregates of gel particles and their uses |
| 06/02/2005 | US20050118268 Timed pulsatile drug delivery systems |
| 06/02/2005 | US20050118267 Chronotherapeutic dosage forms |
| 06/02/2005 | US20050118266 pharmaceutically active agent intermixed with a pharmaceutically acceptable water-insoluble, but water-permeable polymeric material; with a second component comprising a mixture of a pharmaceutically active agent and at least 2% (w/w) of a water-insoluble, water-impermeable hydrophobic material |
| 06/02/2005 | US20050118265 Antifungal oral dosage forms and the methods for preparation |
| 06/02/2005 | US20050118264 matrix tablet dosage form, in which Venlaxfaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with a polymeric layer which enables the controlled release; antidepressant |
| 06/02/2005 | US20050118262 Controlled release formulation |
| 06/02/2005 | US20050118261 Compositions and methods of administering doxepin to mucosal tissue |
| 06/02/2005 | US20050118259 stabilized by use of excipients comprising a basic compound, preferably an alkali-oralkaline earth metal carbonate, and an insoluble alkaline-earth metal carbonate, and an insoluble alkaline-earth metal hydrogen phosphate |
| 06/02/2005 | US20050118258 Pharmaceutical composition comprising skim milk powder |
| 06/02/2005 | US20050118257 Dosing a hyperlipidemic with an effective anticholesterol amount of nicotinic acid once per day in the evening or at night; combined with a pharmaceutically acceptable carrier to form an oral solid dosage form; side effect reduction |
| 06/02/2005 | US20050118256 Extended release alpha-2 agonist pharmaceutical dosage forms |
| 06/02/2005 | US20050118254 hydrophilic solvent, an oil, and a surfactant, and a pharmaceutically active component; hydrophilic solvent selected from the group consisting of propylene glycol diacetate, propylene glycol monoacetate, and salts |
| 06/02/2005 | US20050118253 comprising a nucleic acid that is fully encapsulated within a lipid; for treating a neoplasia in a mammal |
| 06/02/2005 | US20050118252 tumor-selective targeting system for drug delivery wherein internalization of the drug occurs only in tumor cells and not in normal cells; causes receptor-mediated endocytosis |
| 06/02/2005 | US20050118250 Lipid carrier compositions with enhanced blood stability |
| 06/02/2005 | US20050118249 Liposomes containing a vesicle forming lipid and an aggreagation preventing component free of cholesterol, and the liposomes contain an encapsulated anticancer drug; osmolarity of intraliposomal aqueous medium =< 500 mOsm/kg less |
| 06/02/2005 | US20050118248 fatty acid chain are derived from natural vegetable oils such as vernonia oil, lesquerella oil and castor oil, in which the several reactive groups such as epoxy, hydroxy and double bonds can be modified to polar and ionic groups |
| 06/02/2005 | US20050118247 Method of making ketoprofen patch delivery system |
| 06/02/2005 | US20050118246 total amount of drug present in the dosage form exceeds the solubility limit of the drug in the matrix; total amount of drug present in the dosage form exceeds the solubility limit of the drug in the matrix |
| 06/02/2005 | US20050118245 allows individual dosing; facility is a perforation |